Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
Harvard Business School
Dow
Medtronic

Last Updated: May 28, 2022

Investigational Drug Information for TD-4208


✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for TD-4208?

TD-4208 is an investigational drug.

There have been 13 clinical trials for TD-4208. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Lung Diseases, Obstructive, Lung Diseases, and Pulmonary Disease, Chronic Obstructive. The leading clinical trial sponsors are Theravance Biopharma, Mylan Inc., and Theravance Biopharma R & D, Inc.

There are forty-nine US patents protecting this investigational drug and two hundred and thirty-nine international patents.

Recent Clinical Trials for TD-4208
TitleSponsorPhase
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDMylan Inc.Phase 3
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPDTheravance BiopharmaPhase 3
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPDTheravance BiopharmaPhase 3

See all TD-4208 clinical trials

Clinical Trial Summary for TD-4208

Top disease conditions for TD-4208
Top clinical trial sponsors for TD-4208

See all TD-4208 clinical trials

US Patents for TD-4208

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TD-4208 See Plans and Pricing Crystalline freebase forms of a biphenyl compound THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-4208 See Plans and Pricing Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-4208 See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
TD-4208 See Plans and Pricing JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-4208 See Plans and Pricing Fused imidazo-piperidine JAK inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
TD-4208 See Plans and Pricing Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) See Plans and Pricing
TD-4208 See Plans and Pricing Biphenyl compounds useful as muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TD-4208

Drugname Country Document Number Estimated Expiration Related US Patent
TD-4208 Australia AU2010273514 2029-07-15 See Plans and Pricing
TD-4208 Brazil BR112012000890 2029-07-15 See Plans and Pricing
TD-4208 Canada CA2765621 2029-07-15 See Plans and Pricing
TD-4208 Canada CA2989129 2029-07-15 See Plans and Pricing
TD-4208 China CN102470130 2029-07-15 See Plans and Pricing
TD-4208 Cyprus CY1117075 2029-07-15 See Plans and Pricing
TD-4208 Denmark DK2453894 2029-07-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
Harvard Business School
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.